Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.